BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35894141)

  • 41. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway.
    Li X; Deng SJ; Zhu S; Jin Y; Cui SP; Chen JY; Xiang C; Li QY; He C; Zhao SF; Chen HY; Niu Y; Liu Y; Deng SC; Wang CY; Zhao G
    Oncotarget; 2016 Feb; 7(5):6000-14. PubMed ID: 26755660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity.
    Weinberg F; Hamanaka R; Wheaton WW; Weinberg S; Joseph J; Lopez M; Kalyanaraman B; Mutlu GM; Budinger GR; Chandel NS
    Proc Natl Acad Sci U S A; 2010 May; 107(19):8788-93. PubMed ID: 20421486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy.
    Smakman N; Veenendaal LM; van Diest P; Bos R; Offringa R; Borel Rinkes IH; Kranenburg O
    Oncogene; 2005 Dec; 24(56):8338-42. PubMed ID: 16091732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
    Bartolacci C; Andreani C; Vale G; Berto S; Melegari M; Crouch AC; Baluya DL; Kemble G; Hodges K; Starrett J; Politi K; Starnes SL; Lorenzini D; Raso MG; Solis Soto LM; Behrens C; Kadara H; Gao B; Wistuba II; Minna JD; McDonald JG; Scaglioni PP
    Nat Commun; 2022 Jul; 13(1):4327. PubMed ID: 35882862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo.
    Ma Y; Gu Y; Zhang Q; Han Y; Yu S; Lu Z; Chen J
    Mol Cancer Ther; 2013 Mar; 12(3):286-94. PubMed ID: 23288781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions.
    Liou GY; Döppler H; DelGiorno KE; Zhang L; Leitges M; Crawford HC; Murphy MP; Storz P
    Cell Rep; 2016 Mar; 14(10):2325-36. PubMed ID: 26947075
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
    Rabi T; Catapano CV
    Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Omega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT Pathway.
    Ding Y; Mullapudi B; Torres C; Mascariñas E; Mancinelli G; Diaz AM; McKinney R; Barron M; Schultz M; Heiferman M; Wojtanek M; Adrian K; DeCant B; Rao S; Ouellette M; Tsao MS; Bentrem DJ; Grippo PJ
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30213082
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Loss of heterozygosity for Kras
    Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
    Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer.
    Wang YP; Zhou W; Wang J; Huang X; Zuo Y; Wang TS; Gao X; Xu YY; Zou SW; Liu YB; Cheng JK; Lei QY
    Mol Cell; 2016 Nov; 64(4):673-687. PubMed ID: 27840030
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1.
    Shen H; Xing C; Cui K; Li Y; Zhang J; Du R; Zhang X; Li Y
    Cell Death Differ; 2017 Jul; 24(7):1253-1262. PubMed ID: 28475173
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer.
    Chu PC; Kulp SK; Bekaii-Saab T; Chen CS
    Small GTPases; 2018 Nov; 9(6):452-456. PubMed ID: 27936345
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells.
    Nishikawa G; Kawada K; Hanada K; Maekawa H; Itatani Y; Miyoshi H; Taketo MM; Obama K
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291140
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug Release.
    Kong C; Li Y; Liu Z; Ye J; Wang Z; Zhang L; Kong W; Liu H; Liu C; Pang H; Hu Z; Gao J; Qian F
    ACS Nano; 2019 Apr; 13(4):4049-4063. PubMed ID: 30912923
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
    Zhang W; Li H; Yang Y; Liao J; Yang GY
    Cancer Lett; 2014 Dec; 355(2):273-80. PubMed ID: 25304374
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
    Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
    Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
    Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
    PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
    [TBL] [Abstract][Full Text] [Related]  

  • 60. KRAS
    Hobbs GA; Der CJ
    Subcell Biochem; 2022; 98():205-221. PubMed ID: 35378710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.